Immunocore Holdings

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q4 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

CRISPR Therapeutics

Castle Biosciences Inc

Monte Rosa Therapeutics

Rigel Pharmaceuticals

These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.

Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy

NB Bancorp Inc

Omnicell

UL Solutions Inc

ZIM Integrated Shipping Services

NBBK, OMCL, ZIM, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on December 12, 2024.

New Strong Buy Stocks for December 12th

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?

monday.com

Rush Street Interactive

ZIM, MNDY, RSI, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on November 26, 2024.

New Strong Buy Stocks for November 26th

GH Research PLC

Intellia Therapeutics

Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise.

3 Fast-Growing Stocks Analysts See Doubling in Price

The average of price targets set by Wall Street analysts indicates a potential upside of 112.6% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.

Immunocore to present at upcoming investor conferences

Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.

Immunocore reports third quarter financial results and provides a business update

Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immunocore (IMCR) Upgraded to Buy: Here's Why

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.

Immunocore to present at the 2024 Cantor Global Healthcare Conference

In Q2 of 2024, sales of Kimmtrak were $75 million, which was a year-over-year increase of 32%. Two expansion opportunities are possible for Kimmtrak, which are using it as an adjuvant for uveal melanoma and 2nd-line advanced cutaneous melanoma. Data from the phase 1/2 study, using brenetafusp for the treatment of patients with high-grade serous ovarian cancer, to be presented as a poster at the upcoming ESMO 2024 conference.

Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak

Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V.

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Mohammed Dar - CMO Michael Yee - Jefferies Elias Lenard - JPMorgan Tyler Van - TD Cowen Eric Schmidt - Cantor Fitzgerald Michael Schmidt - Guggenheim Jack Allen - Baird Justin Zelin - BTIG Jonathan Chang - Leerink Securities Ahu Demir - Ladenburg Thalmann Avantika Joshi - Mizuho Naureen Quibria - Capital One Securities Rajan Sharma - Goldman Sachs Ethan Markowski - Needham & Company Operator Welcome to the Immunocore Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript

Talos Energy Inc

Wolfspeed

The Federal Reserve seems prepared to cut interest rates, perhaps by its next meeting in September. That's one reason that institutional dollars are starting to rotate into small-cap growth stocks.

3 Small-Cap Stocks with Significant Growth Potential

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.

Immunocore to present at the Jefferies Global Healthcare Conference

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

Gilead Sciences

Moderna

The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.

Immunocore reports first quarter financial results and provides a business update

Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.

News for Immunocore Holdings Stock (IMCR)